3
Announcements
Trials
Browse
Landscape
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
2
Sponsor
Cancer Type
Other hematologic neoplasm
5
Lymphoid
5
Myeloid
4
Other solid neoplasm
2
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Solid Tumor
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Injections
54
pembrolizumab
40
Carboplatin
20
Bevacizumab
19
Cyclophosphamide
17
toripalimab
14
Nivolumab
14
Cisplatin
14
tislelizumab
13
fludarabine
13
Specimen Handling
13
Paclitaxel
13
Interviews as Topic
13
Pemetrexed
12
Standard of Care
11
Practice Guidelines as Topic
11
Oxaliplatin
11
Fluorouracil
10
Cetuximab
10
atezolizumab
9
Educational Status
9
Docetaxel
9
Capecitabine
9
Leucovorin
8
Methods
7
Etoposide
7
Early Intervention, Educational
7
spartalizumab
6
olaparib
6
Ipilimumab
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Blood Component Removal
×
Other solid neoplasm
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled
NCT07137312
2025-12-23
Ex Vivo Expansion (ACT-X)
Mayo Clinic
Recruiting
24 enrolled